Consistently, our results proved that, in an immune-competent mice model, knocking down TREM2 on TAMs potentiates the anti-PD-L1 therapy, as TREM2 knockdown on macrophages and anti-PD-L1 combined therapy significantly inhibits tumor growth and the accumulation of exhausted CD8+ T cells than anti-PD-L1 alone. This evidence concerns the gene CD8A and neoplasm.